Conversion Labs, Inc.
Conversion Labs, Inc. is listed today as LifeMD, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2020 | $16 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Aug 2020 | $4 M | Private placement after listing | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company LifeMD, Inc., its revenue in fiscal 2025 came from these business segments: Telehealth $194.06 million (100%), Telehealth Subscription Revenue $113.27 million (58%).
Annual report (SEC XBRL) · Dec 2025
Conversion Labs, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Other.
SEC Form D · Nov 2020
Products and services#
No products or services of Conversion Labs, Inc. are on record.
Investors#
No investor of Conversion Labs, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding LifeMD, Inc. shares, as of Sep 30, 2026.
- Federated Hermes, Inc.$12 M8.38%
- BlackRock, Inc.$9 M6.25%
- Vanguard Capital Management LLC$5 M3.56%
- State Street Corp$4 M2.67%
- Geode Capital Management, LLC$3 M2.21%
- Renaissance Technologies LLC$3 M2.05%
- Prescott Group Capital Management, L.L.C.$3 M1.86%
- Marshall Wace, LLP$2 M1.67%
- Tudor Investment Corp Et Al$1 M0.94%
- Susquehanna International Group, LLP$1 M0.84%
- Morgan Stanley$1 M0.74%
- Northern Trust Corp$1 M0.73%
- Citadel Advisors LLC$1 M0.69%
- Vanguard Fiduciary Trust Co$1 M0.62%
- Vanguard Portfolio Management LLC$1 M0.58%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Juan Manuel Pineiro Dagnery | Chief Financial Officer | Nov 2020 |
| Justin Schreiber | Chief Executive Officer | Nov 2020 |
| Nicholas Manuel Alvarez | Chief Acquisition Officer | Nov 2020 |
| Stefan Manuel Galluppi | Chief Operating Officer and Chief Technology Officer | Nov 2020 |
| Bertrand Manuel Velge | Director | Nov 2020 |
| Dr. Joseph V DiTrolio | Director | Nov 2020 |
| Eleanor C. Mariano | Director | Nov 2020 |
| Happy Manuel Walters | Director | Nov 2020 |
| John Manuel Strawn | Director | Nov 2020 |
| Justin Schreiber | Chief Executive Officer | Nov 2020 |
| Roberto V Simon | Director | Nov 2020 |
| Stefan Manuel Galluppi | Chief Operating Officer and Chief Technology Officer | Nov 2020 |
| Anthony Manuel Bruzzese | Director | Sep 2020 |
| Dr. Joseph V. DiTrolio | Director | Sep 2020 |
| Michael Manuel Borenstein | Director | Sep 2020 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.